Source-grounded facts extracted from RECURSION PHARMACEUTICALS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
RECURSION PHARMACEUTICALS, INC. updated its first quarter ended March 31, 2026 guidance (reaffirmed).
“today reported business updates highlighting strong continued pipeline execution, clinical progress and platform advancement, as well as financial results for its first quarter ended March 31, 2026.”
Christopher Gibson departed as Chair of the Board of Directors at RECURSION PHARMACEUTICALS, INC..
“On April 28, 2026, Christopher Gibson, Ph.D., Chair of the Board of Directors (the “Board”) of Recursion Pharmaceuticals, Inc. (the “Company”) and a member of the Research and Development Committee, Technology Committee, and the Corporate Social Responsibility Committee of the Board, informed the Company that he will not stand for re-election to the Board as a Class II Director at the 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).”
RECURSION PHARMACEUTICALS, INC. announced a restructuring with charges of approximately $11 million (approximately 20%).
“into the fourth quarter of 2027. These changes are expected to result in a workforce reduction of approximately 20%. The Company estimates that it will incur approximately $11 million in charges in connection with the workforce reduction, consisting of severance payments, employee benefits, and related costs, substantially all of which the Company expects to”
Dr. Namandjé Bumpus was appointed as Director at RECURSION PHARMACEUTICALS, INC..
“The Board appointed Dr. Bumpus as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as a member of the Nominating Committee of the Board, the Research and Development Committee of the Board, and the Technology Committee of the Board.”
Elaine Sun was appointed as Director at RECURSION PHARMACEUTICALS, INC..
“The Board appointed Ms. Sun as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as the Chair of the Audit Committee of the Board and as a member of the Compensation Committee of the Board.”
Franziska Michor was appointed as Class II Director at RECURSION PHARMACEUTICALS, INC..
“the Board increased the number of members of the Board from 7 to 8 and appointed Franziska Michor, Ph.D., (“Dr. Michor”) as a Class II Director of the Board”
Ben Taylor was appointed as Chief Financial Officer of the Company and President of Recursion UK at RECURSION PHARMACEUTICALS, INC..
“Ben Taylor On November 20, 2024, the Board appointed Ben Taylor (“Mr. Taylor”), age 47, as Chief Financial Officer of the Company and President of Recursion UK, effective as of November 20, 2024.”
Michael Secora changed role as Chief Financial Officer at RECURSION PHARMACEUTICALS, INC..
“Michael Secora On November 20, 2024, the Company announced that Michael Secora (“Dr. Secora”), Chief Financial Officer of the Company, will be transitioning from his role as Chief Financial Officer, effective as of November 20, 2024.”
Terry-Ann Burrell resigned as Director and Chair of Audit Committee at RECURSION PHARMACEUTICALS, INC..
“On August 6, 2024, Terry-Ann Burrell informed the Company’s board of her decision to resign as a member of the Company’s board and Chair of its Audit Committee, effective August 12, 2024.”
Robert Hershberg changed role as Chair of the Board at RECURSION PHARMACEUTICALS, INC..
“the Board elected Robert Hershberg, M.D., Ph.D. as the Chair of the Board, effective at the 2024 Annual Meeting”
R. Martin Chavez departed as Chair of the Board at RECURSION PHARMACEUTICALS, INC..
“R. Martin Chavez, Ph.D., Chair of the Board and member of the Audit Committee of the Board, informed the Company that he will no longer stand for re-election to the Board as a Class III Director at the 2024 Annual Meeting of Stockholders”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.